1. Home
  2. JFIN vs KPTI Comparison

JFIN vs KPTI Comparison

Compare JFIN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$4.05

Market Cap

201.5M

Sector

Finance

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$9.50

Market Cap

194.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
KPTI
Founded
2011
2008
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.5M
194.8M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
JFIN
KPTI
Price
$4.05
$9.50
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$16.00
AVG Volume (30 Days)
75.3K
426.0K
Earning Date
06-03-2026
05-04-2026
Dividend Yield
17.47%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$146,067,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$22.36
P/E Ratio
$1.35
N/A
Revenue Growth
N/A
0.57
52 Week Low
$3.70
$3.65
52 Week High
$18.70
$10.99

Technical Indicators

Market Signals
Indicator
JFIN
KPTI
Relative Strength Index (RSI) 42.97 58.40
Support Level $3.80 $5.43
Resistance Level $4.54 $9.58
Average True Range (ATR) 0.23 0.76
MACD -0.00 0.02
Stochastic Oscillator 36.98 62.00

Price Performance

Historical Comparison
JFIN
KPTI

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Share on Social Networks: